Patent · US Active

Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor

US11999993B2 · kind B2 · utility

0Cited by

5References

8Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Dirk Brehmer · Glückstadt, DE
Lijs Beke · Ekeren, BE
Dana Suzanne Gaffney · Green Lane, US
Christopher H. Moy · Schwenksville, US

Key dates

Filing date	Feb 10, 2022
Grant date	Jun 4, 2024
Priority date	—
Expiry date	Feb 10, 2042

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A90/10
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present disclosure describes methods of identifying a patient that is likely to be responsive to treatment with a protein arginine N-methyltransferase 5 (PRMT5) inhibitor. The methods include evaluating a biological sample from the patient for the presence of a spliceosome mutation or alteration, wherein the presence of the alteration indicates a higher likelihood for the patient to be responsive to treatment with the PRMT5 inhibitor than in the absence of the mutation or alteration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.